Subacute Thyroiditis in COVID-19 Patients

Resuli, Ali Seyed; Bezgal, Muzaffer

doi:10.1177/01455613211012114

Cited by 18 publications

(7 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inflammation markers, namely SER and CRP, are positive in the majority of SAT cases, but we did not detect any difference among COVID-19 and SAT patients. In accordance, current data have failed to document any clear correlation between the clinical presentation of SAT after COVID-19 infection and inflammatory markers, nor was a highly suggestive marker of potential thyroid comorbidities identified in a patient developing coronavirus infection [30,[39][40][41][42].…”

Section: Subacute Thyroiditis Induced By Covid-19 Infectionmentioning

confidence: 40%

Clinical Aspects in Subacute Thyroiditis: A Real-Life Study on 226 Cases in Greece Amid the COVID-19 Pandemic

Angelopoulos,

Askitis,

Androulakis

et al. 2023

JCM

View full text Add to dashboard Cite

Purpose: This study aimed to evaluate various therapeutic approaches, identify potential predictive factors for the recurrence and development of hypothyroidism, and examine specific clinical and laboratory characteristics of patients with subacute thyroiditis (SAT) due to SARS-CoV-2 infection. Methods: We retrospectively analyzed the medical records of 226 patients with confirmed SAT diagnosed from January 2020 to November 2022. Results: The mean age was 48.01 ± 0.75 years, and the F/M ratio was 2.3/1. At the end of the follow-up period, 69 patients (32.1%) had developed hypothyroidism. Treatment duration was significantly shorter with nonsteroidal anti-inflammatory drugs (NSAIDs) (17.40 ± 2.56 days), while time-to-symptom relief was shorter with glucocorticoids (CGs). Recurrence was observed only in those treated with corticosteroid preparations (14.1%). C-reactive protein levels at treatment discontinuation were higher in patients who experienced SAT recurrence, while the coexistence of Hashimoto’s thyroiditis was a significant predictive factor for the development of hypothyroidism. The TSH value at the time of treatment withdrawal >4.12 μIU/mL showed optimal sensitivity and specificity for the prediction of permanent hypothyroidism. Regarding COVID-19, 34 patients (15%) experienced related SAT, with similar clinical manifestations of the disease but a higher BMI and shorter time-to-symptom relief. Conclusion: In conclusion, GCs administration alleviated acute symptoms earlier during the onset of SAT, whereas NSAIDs had a shorter treatment duration, and both regimens could not prevent the development of delayed hypothyroidism. The clinical characteristics of SAT due to COVID-19 infections were similar to those of typical SAT disease.

show abstract

Section: Subacute Thyroiditis Induced By Covid-19 Infectionmentioning

confidence: 40%

Clinical Aspects in Subacute Thyroiditis: A Real-Life Study on 226 Cases in Greece Amid the COVID-19 Pandemic

Angelopoulos,

Askitis,

Androulakis

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

“…Female-to-male ratio was 3.6:1 (29 females, 8 males), average age 38.5 (range 18 to 69; Table 1). SAT symptoms can copresent with a positive SARS-CoV-2 PCR or even co-occur with the symptoms of COVID-19, which has never been described before in cases of the previously mentioned SAT-causing viruses (3,4,7,9,11,13,15,18,19). The longest period from COVID-19 infection to SAT onset was 49 days.…”

Section: Discussionmentioning

confidence: 70%

“…By May 2021, more than 170 000 000 people were infected with SARS-CoV-2. In addition, 37 cases of SAT, a rare complication of SARS-CoV-2 infection, have been reported in the literature (Table 1) (2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20). On the other hand, it is also important to highlight, as declared in a position statement from the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism, well-controlled hypo-and hyperthyroidism are not associated with an increased risk of COVID-19 infection or severity (21).…”

Section: Introductionmentioning

confidence: 99%

Subacute thyroiditis associated with COVID-19 infection: a report of an increasing entity

Hajósi-Kalcakosz¹,

Dénes²,

Góth³

2022

Archives of Endocrinology and Metabolism

View full text Add to dashboard Cite

In March 2020, the World Health Organization characterized COVID-19 as a pandemic. By May 2021, 37 cases of subacute thyroiditis (SAT) associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had been reported in the literature. We report a patient diagnosed with SAT associated with COVID-19 and review the previously reported cases. A 31-year-old female with no significant previous history developed SAT 5 weeks after SARS-CoV-2 infection. She presented with anterior neck pain and fever. Thyroid function tests revealed hyperthyroidism with slightly increased inflammatory markers. Thyroid ultrasound showed diffuse hypoechoic left lobe and a hypoechoic area in the right lobe. On the fine-needle-aspiration biopsy, large histiocytes, disrupted and normal follicles, and multinucleated giant cells within colloid were seen. Under oral corticosteroid therapy, clinical progression was rapid. Seven weeks later, all thyroid function tests and inflammatory markers normalized. During the recent viral outbreak, clinicians should keep in mind the possibility of SAT after COVID-19, and patients with symptoms of SAT should be tested for SARS-CoV-2.

show abstract

“…There are reports that COVID-19 can affect the endocrine system and trigger changes in thyroid function, with clinical and biochemical manifestations and the development of antithyroid antibodies. (22,23). One of the cases (#40) that recurred after the infectious episode presented endocrinological manifestations of CD, with the presence of anti-TPO.…”

Section: Discussionmentioning

confidence: 99%

COVID-19 Impact in Crohn’s Disease Patients Underwent Autologous Hematopoietic Stem Cell Transplantation

Ruiz¹,

Kaiser²,

Piron-Ruiz

et al. 2023

Preprint

View full text Add to dashboard Cite

SARS COV 2 is the virus responsible for COVID-19, a disease that has been blamed for inducing or exacerbating symptoms in patients with autoimmune diseases. Crohn's disease (CD) is an inflammatory bowel disease that affects genetically susceptible patients who develop an abnormal mucosal immune response to the intestinal microbiota. Patients who underwent Hematopoietic Stem cell Transplantation are considered at risk for COVID-19. The objective of this report was to describe for the first time the impact of COVID-19 in a group of 50 patients with Crohn's Disease (CD, 28 females, and 22 male) with a mean age of 38 years, previously submitted to Autologous, non-myeloablative, Hematopoietic Stem Cell Transplantation (Auto HSCT) between 2013 and 2021. In this series, 19 patients were diagnosed with positive COVID-19. In two (2) patients there was a report of the occurrence of two infectious episodes. Parameters related to HSCT, such as time elapsed since the procedure, vaccination status, CD status before and after infection, and clinical manifestations resulting from COVID-19, were evaluated. Among the patients with COVID-19, in three, submitted to Auto HSCT less than six (6) months ago, there was a change in the CD status, and one of them, in addition to the CD symptoms, started to present thyroid impairment with positive anti-TPO. Only one of the patients required hospitalization for five days to treat COVID-19 and remained in CD clinical remission. Nine patients reported late symptoms that may be related to COVID-19. There were no deaths, and the statistical evaluation of the series of COVID-19 patients after HSCT and those who did not present an infectious episode did not present significant data regarding the analyzed parameters. Despite the change in CD status in three patients and the presence of nine patients with late symptoms, we can conclude that there was no significant adverse impact concerning COVID-19 in the evaluated patients who underwent HSCT to treat CD. Key Words: Inflammatory bowel disease, Crohn Disease, SARs COV 2, COVID - 19, Autologous Hematopoietic Stem Cell Transplantation, Stem Cell Therapy.

show abstract

Subacute Thyroiditis in COVID-19 Patients

Cited by 18 publications

References 23 publications

Clinical Aspects in Subacute Thyroiditis: A Real-Life Study on 226 Cases in Greece Amid the COVID-19 Pandemic

Clinical Aspects in Subacute Thyroiditis: A Real-Life Study on 226 Cases in Greece Amid the COVID-19 Pandemic

Subacute thyroiditis associated with COVID-19 infection: a report of an increasing entity

COVID-19 Impact in Crohn’s Disease Patients Underwent Autologous Hematopoietic Stem Cell Transplantation

Contact Info

Product

Resources

About